| Item Type | Name |
|
Concept
|
CD11 Antigens
|
|
Concept
|
CD56 Antigen
|
|
Concept
|
Antigens, CD
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Antigens, CD34
|
|
Concept
|
Antigens, CD19
|
|
Concept
|
Antigens, CD20
|
|
Concept
|
CD47 Antigen
|
|
Concept
|
CD3 Complex
|
|
Concept
|
CD5 Antigens
|
|
Academic Article
|
CD5+, CD11c+, CD20+ hairy cell leukemia.
|
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
|
Academic Article
|
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
|
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
|
Academic Article
|
Influence of related donor age on outcomes after peripheral blood stem cell transplantation.
|
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
|
Academic Article
|
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.
|
|
Academic Article
|
Should immunologic strategies be incorporated into frontline ALL therapy?
|
|
Academic Article
|
CD5+ immunophenotype in the bone marrow but not in the peripheral blood in a patient with hairy cell leukemia.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
"Dar"-ing to target CD38 in T-ALL.
|
|
Academic Article
|
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
|
|
Academic Article
|
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
|
|
Academic Article
|
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
|
|
Academic Article
|
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
|
|
Academic Article
|
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
|
|
Academic Article
|
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
|
|
Academic Article
|
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
|
|
Academic Article
|
A phase II trial of interleukin-2 in myelodysplastic syndromes.
|
|
Academic Article
|
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.
|
|
Academic Article
|
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
|
Concept
|
CDX2 Transcription Factor
|
|
Academic Article
|
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
|
|
Academic Article
|
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
|